TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05795465: A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)

Sponsor: GEn1E Lifesciences · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 52 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,460,800

Rescue Site Savings

+$962,800

Unlock Full NCT05795465 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05795465 Rescue Dossier →